GSK Publishes Annual Report and Responsible Business Supplement 2017

Mar 20, 2018 9:00 AM ET

“Our company has an important purpose, to help people do more, feel better, live longer. We have a long history in tackling some of the world’s biggest health challenges. I know this is important to employees, and it was certainly important for me when I joined the company. Our commitment to improving global health and being a responsible business will continue under my leadership.

Investors, patients and consumers, employees and communities rightly expect companies to consider their social impact as well as financial impact as they seek to create value over the long term. Since starting in this role, I have taken the opportunity to understand the views of a broad range of stakeholders. The feedback I received played a big part in the development of our new, balanced set of long-term priorities for GSK – Innovation, Performance and Trust. We are investing in all three to deliver financial returns and a broader long-term societal contribution.”

Emma Walmsley, Chief Executive Officer, GSK  
Responsible business highlights 2017

By being commercially successful and operating responsibly, we will improve people’s health and create value for both shareholders and society.
The Responsible Business Supplement provides a performance update on our 23 responsible business commitments across four key focus areas: Health for all, Our behaviour, Our people and Our planet. It is supplemental to the information in GSK’s Annual Report.  

  • Developing treatments for HIV: We received FDA approval for Juluca, the first 2-drug regimen, once daily, single pill treatment for HIV, with the potential to make a significant difference to the lives of people living with HIV.
  • Reducing child mortality: We have reached 2.7 million children in 41 countries with life-saving interventions since the beginning of our five-year partnership with Save the Children.
  • Training health workers: We achieved our goal three years early to reach 20 million under-served people by 2020 through training frontline health workers.
  • Addressing cold chain challenges: The new design of our Synflorixvaccine means that it lasts 28 days after opening, rather than six hours. This means that clinics and health workers will be able to vaccinate more children per vial.
  • Tackling antimicrobial resistance: In 2017, we trained over 21,000 healthcare professionals on responsible use of antibiotics. In our Pharmaceuticals pipeline, gepotidacin, is the first in a new class of antibiotics.
  • Neglected tropical diseases: By the end of 2017, we had donated nearly eight billion albendazole tablets to prevent lymphatic filariasis and intestinal worms since 1999.
  • Transparent clinical trials: We were ranked no.1 in the AllTrials Transparency Index, building on our long-standing commitment to transparency in clinical trials.
  • Working with third parties: Our Third Party Oversight programme was successfully rolled out to 95% of our third parties. We are on track to reach 100% by early 2018.
  • Employee engagement: Engagement levels have increased significantly since our last global employee survey, with 85% of employees proud to work for GSK and 76% recommending it as a great place to work. 
  • Inclusive workplace: We ranked 21st in the UK Stonewall Workplace Equality Index, which lists the top 100 most LGBT+ and inclusive employers in the UK for 2017.
  • Carbon emissions: We have cut operational carbon emissions by 21% since 2010. Total value chain emissions have risen by 4% as we extend access to our medicines, and we are working to address this.
  • Water use: We are using 22% less water than in 2010, but in 2017 we used 1% more water than in 2016.

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  
We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.  
For further information please contact:

Read the Report